Ivermectin and Cancer: New Studies and Methods of Treatment

Ivermectin and cancer trials

Does Ivermectin (IVM) have anti-cancer properties? How effective is it? What are the study results? Let’s look into it.

According to statistics, over 140,000 cases of cancer are recorded every 12 months in Australia. So, the development of advanced therapies and the search for innovative anti-tumor drugs are of great interest to the scientific community.

During cancer trials, Ivermectin demonstrated promising results. Scientists have found that the drug has a broad spectrum of action, including a strong anti-cancer effect.

The mechanism of action of IVM is not fully understood. Based on preclinical studies (see Table 2), you can say with some confidence that this drug works by inhibiting:

  • Akt/mTOR pathway;
  • Cancer stem cells;
  • DDX23 helicase;
  • HSP27;
  • KPNB1 protein;
  • MAPK pathway;
  • PAK1 protein;
  • P-glycoprotein and MDR protein;
  • SIN3 domain;
  • Wnt pathway;
  • YAP1 protein.

You should continue testing Ivermectin and cancer study, which will contribute to the accumulation of reliable data. It will allow you to examine all the possibilities of a new therapy method.

Ivermectin For Cancer In Humans

Let’s consider the effectiveness of the drug within a clinical pharmacology program. We found the following information on the statistics of diseases and the drug’s action.

Ivermectin for prostate cancer (PCa)

PCa is one of the cell diseases most often diagnosed in Australian men (with over 18,000 cases reported every year).

It is believed that IVM may improve the effect of Xtandi oral tablets (see subsection 2.3). Xtandi (generic name Enzalutamide) prevents hormone production and helps slow the growth of malignant cells, including those that have already spread to nearby tissues.

Ivermectin for brain cancer (BnCa)

According to some data (subsection 2.6), IVM can counter such tumor processes as:

  • Angiogenesis.
  • Metastasis.

Scientists have concluded that IVM can stop the rapid growth of malignant cells, but the prospects for such a treatment method are not yet optimistic.

According to statistics, about 1,900 persons fall ill with BnCa in Australia every year.

Ivermectin for breast cancer (BCa)

According to preclinical experiments, IVM significantly inhibits the growth of malignant cells by affecting the tumor microenvironment (subsection 2.1). It is one of the newest trends in the study and development of anti-cancer drugs.

In Australia, approximately 20,000 cases of BCa are reported annually.

Ivermectin for liver cancer (LCa)

According to some experiments, IVM blocks the activity of YAP1 (yes-associated protein 1). This protein plays an important role in the development of LCa.

Every year about 2,800 Australians, mostly men, are diagnosed with secondary and primary LCa.

Ivermectin For Cancer: Dosage & Treatment

It is clear that the therapeutic effects of any drug are dose-dependent. Understandably, the Ivermectin dosage for prostate cancer should differ from the dosage for other types of cancer.

However, it is impossible to determine the optimal dose of Ivermectin for cancer and the frequency of tablet use. A new drug must first pass all clinical studies, and then the TGA can certify it.

Can Ivermectin Cause Cancer

We found no evidence of a relationship between Ivermectin and cancer. The instructions for the drug don’t mention such a side effect. Instead, the drug demonstrates anti-tumor effects supported by published reports.

Conclusion

Cancer is a group of non-infectious related diseases in which groups of body cells begin to divide continuously and spread to surrounding tissues. It can develop in any tissue and affect various parts of the body.

Evaluating IVM’s usefulness, safety, and toxicity in people with cancer requires full-scale clinical trials. If they are successful, this drug will be approved for cancer treatment.